Literature DB >> 1653756

Characterization of nucleotide sequences from European hepatitis C virus isolates.

K Fuchs1, M Motz, E Schreier, R Zachoval, F Deinhardt, M Roggendorf.   

Abstract

We characterized the 5' end and parts of the structural genes of European isolates of hepatitis C virus (HCV) and compared them with recently published RNA sequences of American and Japanese HCV isolates. The cDNA, obtained by reverse transcription of viral RNA extracted from different sera, was amplified by nested PCR, cloned and sequenced. Within 239 nucleotides (nt) of the 5' end, we found only three single-nt exchanges compared to two sequences of Japanese origin and one exchange to the prototype HCV sequence (ptHCV) (homology greater than 99%). The sequence of the core region (534 nt) in two European isolates showed a homology of about 97-98% on the nt level, as compared to ptHCV and one Japanese isolate, and 90% to other Japanese isolates. The amino acid (aa) homology was between 98-99% among all published sequences. A greater discrepancy was found in the European isolates within the 434 nt sequenced from the N-terminus of the putative envelope region, where the nt homology to ptHCV and one Japanese isolate was 90-93% (aa homology 93-95%), and to other Japanese isolates was 72-73% (aa homology 77-78%), indicating that the European isolates may be more closely related to the ptHCV and one Japanese isolate than to the other Japanese isolates. Amplified genes encoding structural proteins (core, envelope) were expressed in Escherichia coli. Sera from chronically infected patients reacted strongly with the recombinant core protein, but no specific immunoreactivity occurred with the putative envelope protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653756     DOI: 10.1016/0378-1119(91)90269-h

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

1.  Approaches of the diagnosis of hepatitis viruses.

Authors:  G J Kotwal
Journal:  Mol Biotechnol       Date:  2000-11       Impact factor: 2.695

2.  Analysing the sequence diversity of the 5' NC-region of HCV-isolates found in southern Germany.

Authors:  M Da Silva Cardoso; S Epple; K Koerner; B Kubanek
Journal:  Eur J Epidemiol       Date:  1994-10       Impact factor: 8.082

3.  Reduction of synonymous substitutions in the core protein gene of hepatitis C virus.

Authors:  Y Ina; M Mizokami; K Ohba; T Gojobori
Journal:  J Mol Evol       Date:  1994-01       Impact factor: 2.395

4.  HCV and HGV infection in Hodgkin's disease.

Authors:  Katalin Keresztes; Mária Takács; Margit Horányi; Zsófia Miltényi; Arpád Illés
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

5.  Prevalence of hepatitis C virus infections in dialysis patients and their contacts using a second generation enzymed-linked immunosorbent assay.

Authors:  U Schlipköter; U Gladziwa; K Cholmakov; A Weise; R Rasshofer; B Lorbeer; N Luz; F Deinhardt; M Roggendorf
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

6.  Demonstration of HCV-RNA and HBV-DNA in the serum of HBsAg negative patients with hepatocellular carcinoma.

Authors:  J Enríquez; K Fuchs; F J Martínez Cerezo; R Seminago; P Madoz; J Torras; M Roggendorf
Journal:  Eur J Epidemiol       Date:  1994-04       Impact factor: 8.082

7.  Sequence analysis of the 5' noncoding region of hepatitis C virus.

Authors:  J Bukh; R H Purcell; R H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

8.  Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region.

Authors:  G Driesel; D Wirth; K Stark; R Baumgarten; U Sucker; E Schreier
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Molecular typing of hepatitis C virus genome from sera and liver tissues of patients with anti-HCV positive chronic liver disease.

Authors:  S K Yoon; Y M Park; K W Chung; B S Kim; C J Kim; W Y Kim; S K Chang; M J Cho
Journal:  Korean J Intern Med       Date:  1993-07       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.